MidWest Drug Development Conference
Downtown Capitol District, Omaha, Neb. | Oct. 1-2, 2018
2018-10-01 08:00:00
Register
Downloads
  • Promotional Flyer
  • Program (Coming Soon!)
  • Map (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • By category
      • Cancer
      • Cardiovascular/Renal
      • Central Nervous System
      • Drug Delivery
      • Infectious Diseases
      • Metabolic
      • Ophthalmology
      • Rare Diseases
      • Startups
      • Pain Management
      • Women’s Health
    • By institution
      • Colorado St.
      • Illinois-Urbana
      • Indiana
      • Iowa
      • Iowa St.
      • Kansas
      • Kansas St.
      • Missouri
      • Nebraska
      • Nebraska Med Center
      • Oklahoma
      • Purdue
      • Wash U
    • Startups
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • By category
      • Cancer
      • Cardiovascular/Renal
      • Central Nervous System
      • Drug Delivery
      • Infectious Diseases
      • Metabolic
      • Ophthalmology
      • Rare Diseases
      • Startups
      • Pain Management
      • Women’s Health
    • By institution
      • Colorado St.
      • Illinois-Urbana
      • Indiana
      • Iowa
      • Iowa St.
      • Kansas
      • Kansas St.
      • Missouri
      • Nebraska
      • Nebraska Med Center
      • Oklahoma
      • Purdue
      • Wash U
    • Startups
  • Sponsors
  • News
  • Contact
  • Meet new partners, unearth hidden gems at the Midwest Drug Development Conference in Omaha, Nebraska, Oct. 1-2, 2018. A dozen major Midwest medical research institutions with their best and brightest technologies will be in one place, including Colorado State University, Indiana University, Iowa State University, Kansas State University, Northwestern University, Purdue University, University of Illinois-Urbana, University of Iowa, University of Kansas, University of Nebraska, University of Missouri and the University of Washington in St. Louis. Those institutions accounted for (in 2016 according to AUTM data): $5.61 billion in research; 2,119 new inventions; 614 licensing agreements; 581 U.S. patents; 42 new products; 91 startups formed; 10 blockbusters (licensing agreements worth $1 million or more).

GOAL OF THE FORUM

The goal of the Midwest Drug Development conference is to provide industry and investors a single event to learn about cutting edge Midwestern therapeutic technologies and start-up companies.

Read more

COVERAGE

The 2018 MWDD conference will offer feature technologies from most major Midwestern universities, including Nebraska and the Nebraska Medical Center, Kansas, Kansas State, Iowa, Iowa State, Illinois, Indiana, Purdue, Washington University, and Colorado State.

Read more

TARGETED NETWORK

Ample spaces dedicated to networking will be available for university, industry and investor guests who want to engage in one-on-one partnering discussions regarding their technologies.

Read more

Don't miss this unique opportunity!

See the best of the Midwest in one spot

Register Now!
Technologies

Featured technologies & Speakers

List is tentative, and subject to change at any time.

SEARCH:

“Undruggable” dimerization domain of survivin targeted for anticancer drugs

QRKAnswer (Indiana University)

Survivin is an ideal target for discovery of anticancer drugs because it is expressed only in cancers but not adult human tissues.

Read more

Antibiotic gel formulation for root canal pathogens

Indiana University

Antibiotic gel formulations, including low concentrations of two antibiotics, are capable of killing root canal pathogens without harming the stem cells inside the root canal.

Read more

Broad spectrum anti-viral therapeutics targeting sphingosine-1 phosphate metabolizing enzymes

University of Missouri

Sphingosine 1-phospate metabolizing enzymes are involved in modulating cellular responses to a variety of viruses in human and veterinary applications. 

Read more

CCL21 nanoparticles for cancer immunotherapy

University of Nebraska Medical Center

Harness the power of the immune system to recruit immune cells to help treat cancer.

Read more

Endocannabinoid derivatives as novel anti-inflammatory and anti-pain drugs

University of Illinois

Stable derivatives of naturally occurring endocannabinoid epoxides that produce some of the same medicinal qualities as marijuana

Read more

Fatty acid uptake inhibitors as targets for obesity therapy

University of Nebraska-Lincoln

A proprietary high-throughput screening method to identify and characterize in-cell based assays compounds that inhibit FATP2 mediated fatty acid uptake.

Read more

Gastric pH control for the treatment of acid-related disorders

University of Missouri

Combination of Proton Pump Inhibitors (PPIs) Omeprazole and Lansoprazole in a buffered composition for 24-hour gastric pH control to treat a variety of acid-related disorders such as Barrett’s Esophagus, Gastroesophageal Reflux Disease, and others. 

Read more

GLUT Inhibitors for treatment of non-alcoholic fatty liver disease

Washington University in St. Louis

This transformative initiative focuses on the development and clinical introduction of a first-in-class drug to safely and effectively treat early stage fatty liver disease.

Read more

Histone deacetylase inhibitors

Cetya Therapeutics (Colorado State University)

Cetya has a portfolio of over 30 analogs of largazole for evaluation in a multitude of therapeutic indications. The largazole scaffold also lends itself to further modification to develop optimized analogs suited to a particular clinical indication.

Read more

Hsp90β selective inhibitors for cancer

University of Kansas

Highly selective Hsp90β inhibitors can be developed for the treatment of a variety of diseases that result from increased Hsp90 expression.

Read more

Immune stimulating peptides

Prommune (University of Nebraska Medical Center)

A unique and patented means to safely and effectively awaken the body’s own natural immune defenses without inflammatory side-effects.

Read more

Improving women’s health with designer estrogens

University of Illinois

Novel estrogens that retain beneficial effects in metabolic tissues without further risks to reproductive tissues

Read more

Long acting antiretroviral therapy

University of Nebraska Medical Center

New delivery method opens powerful option for HIV treatment

Read more

Low-dose therapeutic for polycystic kidney disease

Indiana University

Pioglitazone, currently approved for treatment of diabetes under the trade name Actos, is effective in delaying cyst growth in polycystic kidney disease (PKD). 

Read more

Method for producing drug nanocrystals

Purdue University

A scaling-up method for producing drug nanocrystals that combines the top-down and bottom-up approaches.

Read more

Mobilization of HIV from lymphatic reservoirs

AllVirEx (Indiana University)

T cell interactions with specific receptors/ligands on lymphatic endothelium are necessary for the egress of T cells from peripheral lymph nodes into the circulation.

Read more

Nano-particulate drug delivery system targeting MM cells through the surface marker CD38

Washington University in St. Louis

More details coming soon!

Read more

Neuroprotection by mitochondria-targeted Metformin

Iowa State University

Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades.

Read more

Next-gen anticancer drugs based on natural compounds

InnoBioPharma (University of Iowa)

InnoBioPharma has developed several novel drug candidates (two in pre-clinical trials) that are particularly effective against aggressive cancers that lack effective drug therapy.

Read more

NF-κB pathway inhibitors

University of Nebraska Medical Center

A molecule capable of specifically inhibiting the NF-κB pathway, a key target involved in a variety of cancers and other diseases.

Read more

Non-opioid for treating chronic pain and opioid dependence

Purdue University

An effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. Compounds may also prevent and/or reduce opioid dependence.

Read more

Novel anthelmintic drugs

Iowa State University
Compounds (S)-5-ethynyl-anabasine and (S)-5-bromoanabasine may take advantage of the large market for animal parasiticides and the lack of existing patented drugs for deworming.
Read more

Novel assay and peptide inhibition of calpain-5 enzyme

University of Iowa

Peptide-based therapeutic agents that inhibit the CAPN5 enzyme.

Read more

Novel broad-spectrum antivirals against noroviruses, picornaviruses and coronaviruses

Kansas State University

Novel inhibitors targeting 3C or 3CL virus proteases.

Read more

Novel cancer immune-based therapy

University of Missouri

Cancers persist only when they evade the host’s immune system.  This novel cancer therapy resensitizes the host immune system to cancer epitopes through a novel method involving vaccination with a treated sample of the biopsied tumor.  Trials in canines have demonstrated efficacy.  Patents pending.

Read more

Novel compounds for angiogenesis-mediated diseases

Indiana University

Wet age-related macular degeneration (AMD) is known to negatively affect aging populations. The disease can result in blindness and can lead to a severe decline in quality of life.

Read more

Novel delivery platform for small molecules, gene therapy agents and others

University of Nebraska-Lincoln

A substrate mediated delivery system for highly controlled local and sustained release of any hydrophobic or hydrophilic cargo.

Read more

Novel kappa opioid-selective ligands for neurological disorders

University of Kansas

More info coming soon!

 

Read more

Novel peptides for therapeutic treatment of injury related to ischemia/reperfusion

Kansas State University

Therapeutic peptides to combat excessive inflammation and tissue damage in response to ischemia/reperfusion (IR).

Read more

POSH inhibitor-based cancer therapy

University of Missouri

Cell-specific non-toxic reagent for the treatment of hematological and other cancers. Data using micelles composed of peptide amphiphiles targeted using aptamers demonstrate efficacy against a wide range of human and canine cancers, as well as low toxicity in vivo, and 2-3x longer median survival.  Patents issued and pending.

Read more

Prostate cancer vaccine

Ohana Vaccines (University of Iowa)

A therapeutic vaccine for patients with recurrent prostate cancer that effectively destroys expressing tumor cells while leaving normal cells unharmed.

Read more

Protease inhibitor drugs with improved PK, bioavailability

Kansas State University

A collaboration between Kansas State University and Wichita State University has led to the development of protease inhibitors with improved pharmacokinetics (PK) and bioavailability using a prodrug approach of peptidyl aldehyde compounds.

Read more

Small molecule regulators of mitochondrial fusion and methods of use

Washington University in St. Louis

More info coming soon!

Read more

SMN2 catalytic core for spinal muscular atrophy treatment

Iowa State University

In humans, there are two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2.  Loss of SMN1 in conjunction with skipping of SMN2 exon 7 in pre-mRNA splicing—which results in a truncated, unstable SMN—leads to spinal muscular atrophy. 

Read more

Splicing correction in spinal muscular atrophy

Iowa State University
A blocking antisense oligonucleotide and its target site located in a deep intronic sequence of the SMN2 gene. The blocking of the SMN2 target sequence corrects the defective splicing of the gene.
Read more

Targeting disease-causing DNA, RNA

University of Illinois

This talk will focus on the design, synthesis, and study of ligands that target DNA and RNA repeat sequences that cause disease.

Read more

Therapy for the reversal of Type I Diabetes

University of Missouri

Combination treatment of Ig-GAD2 and stem cells to cure Type I Diabetes (TID).  Data demonstrate a functional cure in a mouse model for TID through restoration of immune tolerance coupled with regeneration of endothelial cells in the pancreatic islets. Patents issued and pending.

Read more

Top1/TDP1/TDP2 Triple inhibitor anticancer agents

Purdue University

Azaindenoisoquinoline compounds that act as inhibitors of Top1, TDP1, and TDP2 for cancer treatment

Read more

TR3 biologics for the treatment of cancer

Washington University in St. Louis

TR3 Technology delivers a new generation of TNF superfamily TRAIL (TNF-related apoptosis-inducing ligand, designated TR3) directly to MUC16-expressing cancer cells.

Read more

Tumor-targeted chemerin fusion protein

Washington University in St. Louis

More info coming soon!

Read more

UGDH as a novel target for castration-resistant prostate cancer

University of Nebraska-Lincoln

Prostate Cancer (PC) is commonly treated with androgen deprivation therapy (ADT), but tumors may become resistant to androgen removal and are then categorized as Castration-Resistant PC (CRPC).

Read more

Unique LKB1-AMPK activator for polycystic kidney disease

University of Kansas

A novel compound and method for treating Polycystic Kidney Disease utilizing a novel liver kinase B1 activator

Read more

Unlock the potential of photodynamic/ultraviolet light therapy

LoDos Theranostics (Purdue University)

LoDos Theranostics has developed “first-in-class” nanoparticles called “Radio-Luminescent Nano Particles (RLNPs)” which will be injected into the tumor before a patient receives radiation treatment: The first product to endogenously deliver UV light to deep tumors. 

Read more

Water soluble glucagon derivative stable at neutral pH

Purdue University

A method of stabilizing glucagon and improving its solubility in aqueous form.

Read more
Schedule

Conference Schedule

Sunday
Sep 30, 2018
TBA
TBA
Welcome Reception

TBA

TBA
Monday
Oct 1, 2018
8:00 — 9:00 a.m.
TBA
Breakfast

Check in at 8 a.m. to take advantage of a full hour of networking along with a complimentary breakfast.

TBA
9:00 a.m. — Noon
Technology Presentations

Details Coming Soon

Noon — 1:00 p.m.
TBA
Lunch

Networking opportunity with complimentary lunch

TBA
1:00 p.m. — 5:00 p.m.
Technology Presentations

Details Coming Soon

5:00 p.m. — 7:00 p.m.
Cocktails

A cocktail mixer for networking. Guests are responsible for their own meals.

Tuesday
Oct 2, 2018
8:00 a.m. — 9:00 a.m.
TBA
Breakfast

Check in at 8 a.m. to take advantage of a full hour of networking along with a complimentary breakfast.

TBA
9:00 a.m. — Noon
Technology Presentations

Details Coming Soon

Noon — 1:00 p.m.
TBA
Lunch

Networking opportunity with complimentary lunch

TBA
1:00 p.m. — 4:00 p.m.
Technology Presentations

Details Coming Soon

4:00 p.m. — 5:00 p.m.
Wrap Up

More Details Coming Soon

Number of participants is limited!

Don't miss your chance. Find the next big thing in Omaha

Register Now!
NewsNewsNews

Latest News

Deadline for presentations rapidly approaching

It’s last call for presentations at the Midwest Drug Development conference, officials announced today.

Only 10 slots remain open in the two-day slate of early- and mid-stage technologies that will be presented to guests from the worlds of biomedical therapeutics and investor groups.

Read more

Registration is now open! Are you attending?

The MidWest Drug Development Conference is now accepting registrations to attend a two-day event focused on highlighting the best early- and mid-stage therapeutic technologies that Midwestern universities have to offer.

Read more

Drug development conference planned

The Midwest Drug Development Conference, a new biomedical partnering event, will come to Omaha next year, officials at the University of Nebraska Medical Center and its technology transfer and commercialization office, UNeMed, announced today.

Read more
View all news
VenueVenueVenue

Venue & Contacts

Hotel website: http://www.downtownomahamarriott.com/

Contacts

Event Coordinators

Matt BoehmIndustry & University Liason

mboehm@unmc.edu | 402-559-2468

Michael DixonSponsors & Donors

mdixon@unmc.edu | 402-559-2468

Send us a message

sponsors

Our Sponsors and Partners

Sponsorship Packages

Platinum Sponsor

  • Table in networking space (6’ table)
  • 4 free registrations
  • Two-page ad in program
  • Logo placement on website and in conference materials
  • Named sponsor for one lunch

Gold Sponsor

  • Table in networking space (6’ table)
  • 3 free registrations
  • Full page ad in program
  • Logo placement on website and in conference materials
  • Named sponsor for one Breakfast

Silver Sponsor

  • Two free registrations
  • Half page ad in program
  • Logo placement on website and in conference materials
  • One Category 3 item included

Bronze Sponsor

  • 1 free registration
  • Quarter page ad in program
  • Logo placement on website and in conference materials
  • One Category 4 item is included

CUSTOMIZE YOUR PLAN!

À la carte options are also available, such as meal sponsorships and advertising placements. Contact Michael Dixon to learn more.

Become a sponsor!

Learn more about how you can help bring academic research to the marketplace!

More Info

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
Downtown Capitol District, Omaha, NE
October 1-2, 2018

Latest News
  • Deadline for presentations rapidly approaching April 19, 2018
  • Registration is now open! Are you attending? February 7, 2018
  • Drug development conference planned February 1, 2018
Twitter Hightlights
  • RT @unmc: Biosciences firm @Taconic licenses Easi-CRISPR, @unmc breakthrough in genome engineering. Transformational work by Dr. Channabasa…
    1 day ago
  • More headlines for Dr. Gurumurthy of @unmc, co-inventor of the Easi-CRISPR technology, which could "revolutionize"… https://t.co/2Q4rjUAO8w
    1 day ago